Interaction of dispersed cubic phases with blood components

Steric Stabilizers for Cubic Phase Lyotropic Liquid Crystal Nanodispersions (Cubosomes)

“…Cubosomes have been studied for administration via ocular, dermal, intradermal, mucosal, intranasal, oral, percutaneous, intraperitoneal, intratympanic, and intravenous routes, as presented in Table 1. In addition, studies have also been performed on the interaction of nanostructured particles with model and cell membranes [102] and blood components [103], for their biocompatibility within the body as effective drug delivery systems. The cryo-FESEM images display the 3D particle morphology of cubosomes and are adapted from Rizwan et al [36].…”

A Novel Chemical Enhancer Approach for Transdermal Drug Delivery with C₁₇-Monoglycerol Ester Liquid Crystal-forming Lipid

“…Previous research has demonstrated that the LC phases of GMO such as the cubic and hexagonal phases, increased transdermal drug delivery. As a transdermal absorption enhancer, GMO probably acts by causing a temporary and reversible disruption of the lamellar structure of the lipid bilayer in the stratum corneum and, in this way, increasing intercellular lipid fluidity 13 .…”

Glycerol monooleate liquid crystalline phases used in drug delivery systems

“…The purpose of this review is to 83 summarize the data about drug delivery systems based on glycerol 84 monooleate liquid crystalline phases (Amar-Yuli et al, 2009;Caboi 85 et al, 2001;Chernik, 1999;Drummond and Fong, 1999;Engström, 86 1990;Fong et al, 2012;Garti et al, 2012;Guo et al, 2010;Hitesh 87 et al, 2011;Kaasgaard and Drummond, 2006;Kulkarni et al, 2011;88 Larsson, 2009;Leser et al, 2006;Sagalowicz et al, 2006a,b;Shah 89 et al, 2001). Furthermore, glycerol monooleate is a nontoxic, biodegradable 109 and biocompatible material, classified as GRAS (generally recog-110 nized as safe) and it is included in the FDA Inactive Ingredients 111 Guide (Bode et al, 2013;Ganem-Quintanar et al, 2000;Matschke 112 et al, 2002). One important aspect of the use of glycerol 113 monooleate as a safe parenteral material is the necessity to 114 confirm its biological tolerance.…”